The Medical Letter on Drugs and Therapeutics
FROM
ISSUE1541
ISSUE1541
February 26, 2018
Odactra - Sublingual Immunotherapy for House Dust Mite-Induced Allergic Rhinitis
Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
Odactra - Sublingual Immunotherapy for House Dust Mite-Induced Allergic Rhinitis
February 26, 2018 (Issue: 1541)
The FDA has approved Odactra (ALK), a sublingual
allergen extract, for immunotherapy in adults 18-65
years old with house dust mite (HDM)-induced allergic
rhinitis, with or without conjunctivitis. Odactra is the
first sublingual allergen extract...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.